Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go
- 1 April 2020
- journal article
- editorial
- Published by Elsevier in European Urology
- Vol. 77 (4) , 434-435
Abstract
No abstract availableFunding Information
- Academy of Medical Sciences
This publication has 11 references indexed in Scilit:
- A Consensus Molecular Classification of Muscle-invasive Bladder CancerEuropean Urology, 2020
- Looking beyond the hype: Applied AI and machine learning in translational medicineEBioMedicine, 2019
- FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.Journal of Clinical Oncology, 2019
- Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant ChemotherapyEuropean Urology, 2019
- ERCC2Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder CancerClinical Cancer Research, 2019
- Bladder Cancer in the Genomic EraArchives of Pathology & Laboratory Medicine, 2019
- Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerCell, 2018
- The consensus molecular subtypes of colorectal cancerNature Medicine, 2015
- Outcome of urinary bladder recurrence after partial cystectomy for en bloc urinary bladder adherent colorectal cancer resectionInternational Journal of Colorectal Disease, 2013
- The importance of platform annotation in interpreting microarray dataThe Lancet Oncology, 2010